Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE.

Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE.

Item
http://www.wikidata.org/entity/Q48892230
Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40LTranslational utility of experimental autoimmune encephalomyelitis: recent developmentsDeveloping therapeutics for the treatment of multiple sclerosisMonoclonal antibodies in multiple sclerosis treatment: current and future steps.Effects of early IL-17A neutralization on disease induction in a primate model of experimental autoimmune encephalomyelitis.Discrepant effects of human interferon-gamma on clinical and immunological disease parameters in a novel marmoset model for multiple sclerosis.Clinical targeting of the TNF and TNFR superfamiliesEnhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental designAn Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40–CD40L interactions with T helper cells
P2860

Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE.

Item
http://www.wikidata.org/entity/Q48892230
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Treatment with chimeric anti-h ...... s affected by MOG-induced EAE.
@en
Treatment with chimeric anti-h ...... s affected by MOG-induced EAE.
@nl
type
label
Treatment with chimeric anti-h ...... s affected by MOG-induced EAE.
@en
Treatment with chimeric anti-h ...... s affected by MOG-induced EAE.
@nl
prefLabel
Treatment with chimeric anti-h ...... s affected by MOG-induced EAE.
@en
Treatment with chimeric anti-h ...... s affected by MOG-induced EAE.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Treatment with chimeric anti-h ...... s affected by MOG-induced EAE.
@en
P2093
P304
P31
P356
10.1016/J.JNEUROIM.2005.02.005
P433
P478
P50
P577
P698
P921